Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biomerica (BMRA) EBITDA Margin (2016 - 2025)

Biomerica's EBITDA Margin history spans 16 years, with the latest figure at 109.17% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5086.0% year-over-year to 109.17%; the TTM value through Nov 2025 reached 90.13%, up 1054.0%, while the annual FY2025 figure was 93.69%, 1656.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 109.17% at Biomerica, down from 0.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 0.29% in Q3 2025 and bottomed at 205.07% in Q2 2025.
  • The 5-year median for EBITDA Margin is 106.64% (2025), against an average of 98.96%.
  • The largest annual shift saw EBITDA Margin surged 12887bps in 2022 before it tumbled -14847bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 24.32% in 2021, then plummeted by -354bps to 110.32% in 2022, then grew by 13bps to 96.17% in 2023, then surged by 39bps to 58.31% in 2024, then tumbled by -87bps to 109.17% in 2025.
  • Per Business Quant, the three most recent readings for BMRA's EBITDA Margin are 109.17% (Q4 2025), 0.29% (Q3 2025), and 205.07% (Q2 2025).